Prevalence of non-valvular atrial fibrillation is increasing over time. Particularly in elderly
population, treatment strategies to reduce the rate of stroke are challenging and still …

Nonvalvular Atrial fibrillation (NVAF) is the most common cardiac arrhythmia associated with
an increase in risk of stroke and systemic thromboembolism. Strokes related to AF are …

Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have
represented the main anticoagulation management for antithrombotic prevention in this …

The majority of patients with atrial fibrillation should receive oral anticoagulation to reduce
the risk of stroke. The limitations of vitamin K antagonists have led to an underuse of …

Thrombosis is a leading cause of mortality in cancer patients. Cancer patients are at an
increased risk of developing atrial fibrillation, and venous thromboembolism is a leading …

Atrial fibrillation is the most common arrhythmia in clinical practice, and elderly patients are
at higher risk of both ischemic and bleeding complications. Vitamin K antagonists (VKAs) …

New oral anticoagulants (NOACs: dabigatran, rivaroxaban, apixaban and edoxaban) proved
to be at least non-inferior to warfarin in reducing thromboembolic risk in patients with atrial …

Direct oral anticoagulants (DOAC) are used in several indications for the prevention and
treatment of thrombotic events. As highlighted by data from clinical trials and case studies …

Одной из важных причин развития ятрогенных лекарственных поражений внутренних
органов является недоучет врачами при выборе лекарственных средств (ЛС) и их …